Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215366 | 0.92 | MEN1 (0.54) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6214981 | 0.91 | MEN1 (0.54) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6639030 | 0.89 | MEN1 (0.51) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6639366 | 0.89 | MEN1 (0.51) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6638524 | 0.89 | MEN1 (0.51) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6641994 | 0.88 | MEN1 (0.51) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6643352 | 0.88 | MEN1 (0.51) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6642256 | 0.88 | MEN1 (0.51) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6640284 | 0.87 | MEN1 (0.57) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6215438 | 0.85 | MEN1 (0.49) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411947-A2 | SALTS OF SUBSTITUTED 1, 2, 3, 4-TETRAHYDROISOQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES | Grünenthal GmbH (DE) | 2004-04-28 | — | — | EP | claimed |
| JP-2003522758-A | — | — | 2003-07-29 | — | — | JP | claimed |
| WO-2003013530-A2 | SALTS OF SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-02-20 | — | — | WO | claimed |
| EP-1254118-A2 | SUBSTITUTED 1,2,3,4- TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES | Grünenthal GmbH (DE) | 2002-11-06 | — | — | EP | claimed |
| WO-2001058875-A2 | SUBSTITUTED 1,2,3,4- TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES | Grünenthal GmbH (DE) | 2001-08-16 | — | — | WO | claimed |
| US-20040224969-A1 | Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds | GRUENENTHAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| EP-1411947-A2 | SALTS OF SUBSTITUTED 1, 2, 3, 4-TETRAHYDROISOQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES | Grünenthal GmbH (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-6699877-B2 | TREATING PAIN, MIGRAINE, AND VARIOUS OTHER DISEASES | GRUENENTHAL GMBH (DE) | 2004-03-02 | — | — | US | disclosed |
| US-20030087926-A1 | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives | GRUENENTHAL GMBH | 2003-05-08 | — | — | US | disclosed |
| WO-2003013530-A2 | SALTS OF SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-02-20 | — | — | WO | disclosed |
| EP-1254118-A2 | SUBSTITUTED 1,2,3,4- TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES | Grünenthal GmbH (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058875-A2 | SUBSTITUTED 1,2,3,4- TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES | Grünenthal GmbH (DE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087926-A1 | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives | SDHA, CACNA1A, GRIN2C | MEN1 416/4885CYP1A2 63/4885CYP3A4 207/4885 |
| US-20040224969-A1 | Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds | OPRK1, SDHA, GRIN2C | MEN1 2157/4885CYP1A2 73/4885CYP3A4 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.